Capricor Therapeutics (CAPR) Stock Price, News & Analysis

Company Overview

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Los Angeles, California, specializing in the development of innovative cell and exosome-based therapies. Since its founding in 2008, Capricor has focused on leveraging its proprietary platforms to address serious, unmet medical needs in cardiovascular and neuromuscular diseases. The company’s research and development efforts center on advancing novel biologics that harness the regenerative and immunomodulatory potential of human cells and extracellular vesicles.

The company’s lead product candidate, CAP-1002, comprises allogeneic cardiosphere-derived cells (CDCs) designed to repair and regenerate damaged heart tissue. CAP-1002 has been evaluated in clinical trials for indications including Duchenne muscular dystrophy-associated cardiomyopathy and acute COVID-19-related respiratory distress. These studies have demonstrated favorable safety profiles and signs of functional improvement, positioning CAP-1002 as a potential therapeutic option in conditions where conventional treatments are limited.

Building on its cell therapy expertise, Capricor is expanding into the rapidly evolving field of extracellular vesicles with its exosome platform. The company’s investigational exosome product candidate, CAP-2003, is engineered to deliver microRNA payloads that modulate key pathways in heart disease and immune response. This approach seeks to capitalize on exosomes’ natural ability to circulate systemically, offering targeted delivery with minimized risk of rejection or off-target effects.

Under the leadership of President and Chief Executive Officer Linda Marbán, Ph.D., Capricor has formed strategic collaborations with academic institutions, government agencies, and industry partners to advance its pipeline. The company’s multidisciplinary team of scientists and clinicians is dedicated to translating cutting-edge discoveries into scalable therapies. With a commitment to rigorous clinical development and manufacturing excellence, Capricor continues to pursue breakthroughs that may transform the standard of care for patients with debilitating cardiovascular and muscular disorders.

Key Stats

• Today's Range: $10.12 to $10.56
• 50-Day Range: $6.35 to $14.23
• 52-Week Range: $3.52 to $23.40
• Volume: 758,397 shs
• Average Volume: 1.98 million shs
• Market Capitalization: $461.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.22
• Consensus Rating: Buy

Capricor Therapeutics Stock Analysis - MarketRank™

Capricor Therapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 325th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Capricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Capricor Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.21) to ($0.75) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Capricor Therapeutics is -7.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Capricor Therapeutics is -7.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Capricor Therapeutics has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

24.97% of the float of Capricor Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Capricor Therapeutics has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Capricor Therapeutics has recently decreased by 7.85%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Capricor Therapeutics does not currently pay a dividend.

Dividend Growth

Capricor Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

24.97% of the float of Capricor Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Capricor Therapeutics has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Capricor Therapeutics has recently decreased by 7.85%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.60

News Sentiment

Capricor Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Capricor Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 2 people have searched for CAPR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.50% of the stock of Capricor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 21.68% of the stock of Capricor Therapeutics is held by institutions.

CAPR Stock Analysis - Frequently Asked Questions

How have CAPR shares performed this year?

Capricor Therapeutics' stock was trading at $13.80 at the start of the year. Since then, CAPR shares have decreased by 26.8% and is now trading at $10.0950.

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) posted its earnings results on Tuesday, May, 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.20. The biotechnology company earned $2.73 million during the quarter, compared to analyst estimates of $3.16 million. Capricor Therapeutics had a negative net margin of 181.71% and a negative trailing twelve-month return on equity of 62.42%.
Read the conference call transcript.

How do I buy shares of Capricor Therapeutics?

Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Capricor Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Capricor Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Moderna (MRNA), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CAPR
• CIK: 1133869
• Web: www.capricor.com
• Phone: 310-358-3200
• Fax: 415-875-7075
• Employees: 101
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $32.22
• High Stock Price Target: $77.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +219.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$40.47 million
• Net Margins: -181.71%
• Pretax Margin: -317.12%
• Return on Equity: -62.42%
• Return on Assets: -48.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.55
• Quick Ratio: 6.55

Sales & Book Value

• Annual Sales: $22.27 million
• Price / Sales: 20.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.20 per share
• Price / Book: 3.15

Miscellaneous

• Outstanding Shares: 45,680,000
• Free Float: 40,881,000
• Market Cap: $461.14 million
• Optionable: Optionable
• Beta: 0.82